Yahoo
OTC Markets OTCPK - Delayed Quote USD

RVL Pharmaceuticals plc (RVLPQ)

0.0000 0.0000 (0.00%)
At close: September 4 at 4:00:00 PM EDT
Chart Range Bar
Loading chart for RVLPQ
  • Previous Close 0.0000
  • Open 0.0000
  • Bid --
  • Ask --
  • Day's Range 0.0000 - 0.0005
  • 52 Week Range 0.0000 - 0.0005
  • Volume 600
  • Avg. Volume 0
  • Market Cap (intraday) 1,114
  • Beta (5Y Monthly) 42.40
  • PE Ratio (TTM) --
  • EPS (TTM) -0.7100
  • Earnings Date (est.) --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

RVL Pharmaceuticals plc operates as a specialty pharmaceutical company in the United States, Argentina, and Hungary. It focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas. It is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults. The company was formerly known as Osmotica Pharmaceuticals plc and changed its name to RVL Pharmaceuticals plc in January 2022. RVL Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.

www.rvlpharma.com

125

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 9/4/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

RVLPQ
0.00%
S&P 500 (^GSPC)
12.75%

1-Year Return

RVLPQ
0.00%
S&P 500 (^GSPC)
18.71%

3-Year Return

RVLPQ
99.99%
S&P 500 (^GSPC)
70.93%

5-Year Return

RVLPQ
100.00%
S&P 500 (^GSPC)
70.18%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY23
Revenue 8.26M
Earnings -23.89M
Profit Margin -289.28%

Q3

FY22

Q4

FY22

Q1

FY23

Q2

FY23

-20M
-10M
0
10M
-250.0%
-200.0%
-150.0%

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (5yr expected)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -184.91%

  • Return on Assets (ttm)

    -23.65%

  • Return on Equity (ttm)

    -182.44%

  • Revenue (ttm)

    36.92M

  • Net Income Avi to Common (ttm)

    -68.27M

  • Diluted EPS (ttm)

    -0.7100

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    19.16M

  • Total Debt/Equity (mrq)

    356.16%

  • Levered Free Cash Flow (ttm)

    -25.56M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: